The evaluation of immunosuppressive regimens in kidney transplant Mongolian recipients / Эрүүл мэндийн лаборатори

Background@#However kidney transplantation has being performed in Mongolia since 2006, because of pre-transplant sensitization, ABO incompatibility, hepatitis B and C virus activation many patients are taken kidney transplantation in abroad. The transplantation centers use own immunosuppressive regimens.@*Objective@#Our aim was to assess the immunosuppressive regimens efficacy and toxicity in kidney transplant Mongolian recipients.@*Methods@#We analyzed data from 96 adult kidney transplant recipients who had taken kidney transplantation in different transplant centers from August 2006 through January 2014. There were 3 kinds of regimens Group I Simulect induction with standard triple /FK506/CyA+MMF/AZA+steroid/, Group II Campath-1H induction with CNI monotherapy and Group III Campath-1H induction with standard triple /FK506/CyA+MMF/AZA+steroid/. We retrospectively collected the post-transplant first two years serum creatinine. The study was performed in 2014. The questionnaire was taken and blood samples collected for determination of tacrolimus through level and for other laboratory tests. The primary end point was the first two years serum creatinine, the secondary end points included rejection episodes, blood through level of tacrolimus and some laboratory findings. @*Results@#The post-transplant first two years serum creatinine levels were significantly different in 3 groups. Group III showed similar results compared to Group I. There was not enough data of biopsy proven acute rejection episodes however group II said more rejections occurred. However participants said that rejection occurred in 15 (15.6%) biopsy was done only 3 (3.1%) cases. Blood through level of tacrolimus was significantly different in three groups. Some laboratory findings showed different between three groups. @*Conclusions@#A regimen of Campath-1H induction with CNI monotherapy (Group II) may be advantageous for short-term renal function and cost effective but there were more rejection complications and increased creatinine. The regimen of Campath-1H induction 11 with standard triple (Group III) may be advantageous for long-term renal function, allograft survival, but there should consider about infection complications and polycythemia. Simulect induction with standard triple could be best choice but transplantations were performed in experienced centers. The study enrolled few cases and cases which were performed at the beginning of transplant program so many things could influence on the result. The study was compared beginner transplant center with experienced centers. Longitudinal cohort study needed in the future.

VASCULAR RECONSTRUCTION DURING KIDNEY TRANSPLANTATION FOR PREVENTING COMPLICATIONS / Мэс засал

Introduction: This article provides areview about techniques and pitfalls of arterialand venous reconstruction during kidneytransplantation. Main reasons of our clinicalstudy are to evaluate vascular variationsof kidney, posttransplantation vascularcomplication incidence and present status ofsurgery outcome.This retrospective researchbased on cross-sectional assessmentofconsecutive 102 kidney transplantation cases,which performed from 2006 to 2015 at theFirst Central Hospital of Mongolia.Materials and methods: Statisticalprocessing andanalysis on posttransplantionpatient history data are made byMicrosoftExcel, SPSS19.0software.Results: Despite rising technicaldifficulties caused by vascular variations,pelvic and inguinal morphology of recipientand the existence of multiple renal arterieskidney transplantation is a safe and highlyefficient procedure.On this article wereexplained 44 kidney transplantation caseswith reconstruction using microvasculartechniques to reconstruct renal arteriesand veins. About 10 different kinds ofreconstructions were done in our practice.Due to investigation of consecutive 102kidney transplanted recipients, 24,51% had avascular anatomical variations. And describedabout 44 vascular reconstructions used inour hospital in case of vascular variations.According to the lit., vascular complicationsranges from 1 to 16%. In our hospital,vascularcomplication of kidney transplantation withmultiple vessels is 4,0-12,0%. Also, incidenceof vascular complication in group with singlevessels from 1.3 to 2.6% and in group withmultiple vessel 4 to 12%.Even it is highcomparing with other international articles;it’s almost in same results. But lymphaticcomplication is higher than others; it showsneeds of careful and accurate dissection ofrecipient site anastomosing vessels.Conclusion: Multiple renal graft’sveselshave been associated with a higher rateof vascular complications, including arterialstenosis and lymphorrhea. It shows needs ofcareful and accurate dissection of recipientsite anastomosing vessels.

Kidney transplantation in Mongolia using effective and economical immunosuppression - a three-year experience.

Between August 2006 and August 2009, 34 ethnic Mongolians were the recipients of a kidney transplant at the Central Clinical Hospital in Ulaanbaatar, Mongolia. In 31 of the operations the donor was either a sibling or parent. In 4 recipients the donors were 2 recently deceased accident victims following controlled cardiac arrest and after next of kin permission. All 4 recipients are alive with life-supporting function. Appropriate legislation was passed in 2008. Thirty-one of the 34 recipients (91%) are alive. The 1-year patient and graft survival is 91% and 82%, respectively. In all cases, recipients received 1 dose of Campath 1 preoperatively followed by monotherapy with either Cyclosporin or Tacrolimus. Due to the remote geographical location of some of the recipients, appropriate serum drug levels were difficult to monitor. Azathioprine was therefore added in the last 13 recipients. Except for acute rejection episodes, no patients received steroid therapy. There were 7 diagnosed and treated acute rejections in the 34 recipients (21%). The mean annual cost of the immunosuppressive therapy period compared favorably with neighboring China and with costs in Spain. We conclude that the use of Campath 1 together with a non-steroid maintenance immunosuppressive regimen provides both economical and acceptable graft and patient survival in a developing country.

Kidney transplantation achievements in Mongolia.

Between August 2006 and August 2009, 33 patients with end-stage renal disease were the recipients of kidney transplantations. The donors were living related 29 operations with 4 recipients of 2 deceased donors following accidents with cardiac arrest controlled after permission by the next of kin. We used standard techniques for the donor and recipient operations. All recipients were prescribed 1 dose of alemtuzumab (Campath 1 H 20-30 mg), peroperatively preceded by 500 mg methylprednisolone. In 2 recipients, a second infusion of Campath 1 was administered on postoperative day 2. On postoperative day 3, we prescribed monotherapy with either cyclosporine (n=29) at a starting dose of 7 mg/kg body weight or tacrolimus (n=6) at a starting dose of 0.7 mg/kg body weight. With the exception of patients treated for an acute rejection episode, no patient received steroid therapy. There were 7 acute rejection episodes, which were treated with 3 consecutive daily doses of methylprednisolone (250 mg). The 1-year patient survival was 94% and 2-year graft survival, 84.8%. We concluded that the use of Campath 1 together with a non-steroid maintenance immunosuppressive regimen provided acceptable graft and patient survival in our developing country.